SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Myriad Genetics Inc. (MYGN) on Monday reported a loss of $27.4 million in its third quarter.
On a per-share basis, the Salt Lake City-based company said it had a loss of 29 cents. Earnings, adjusted for stock option expense and non-recurring costs, were less than 1 cent on a per-share basis.
The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 1 cent per share.
The molecular diagnostic company posted revenue of $205.7 million in the period, also surpassing Street forecasts. Four analysts surveyed by Zacks expected $205.2 million.
Myriad expects full-year results to range from a loss of 2 cents per share to earnings of 2 cents per share, with revenue in the range of $818 million to $828 million.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MYGN at https://www.zacks.com/ap/MYGN
Copyright © 2025 The Associated Press. All rights reserved. This material may not be published, broadcast, written or redistributed.
